In this Journal of Opioid Management op-ed, Center for U.S. Policy Senior Fellow Lynn Webster, M.D., and co-authors explain that state licensing boards and civil lawsuits, along with the federal government’s administrative framework, are more appropriate forums than federal criminal courts when dealing with questions surrounding medical care
Thirty-three not-for-profit organizations sent a letter to commend Members of Congress for introducing a bill to provide Medicare coverage and create a new Medicaid payment category for prescription digital therapies. The “Access to Prescription Digital Therapeutics Act of 2022” is sponsored by Sens. Jeanne Shaheen (NH) and Shelley Moore Capito (WV), and Reps. Mike Thompson (CA-5) and David McKinley (WV-01).
The Center for U.S. Policy, Aimed Alliance, and the International Health Facility Diversion Association commended the federal government for facilitating patient access to prescription digital behavioral therapies. “We thank CMS for acting with speed to expand access to evidence-based digital therapies for behavioral health.”
SCOTUS sides with the petitioner and Health Law Professors in Ruan v. United States 9-0 ruling that CSA Section 941 has a scienter requirement. More commentary to follow after I give it a close read. Opinion by Justice Breyer here: https://www.supremecourt.gov/opinions/21pdf/20-1410_1an2.pdf
We oppose the DOJ’s indiscriminate raids and prosecutions of prescribers and pharmacists. State licensing boards, not federal law enforcement, should investigate questions of medical need and patient care. @NPR @CredderApp
https://www.npr.org/sections/health-shots/2021/11/08/1053579556/dea-suboxone-subutex-pharmacies-addiction
We had the honor and privilege to speak at #RxSummit2022 about the need to ensure that #opioid litigation proceeds go toward #substanceusedisorder #prevention, #treatment, #harmreduction, and #recovery support. @RxSummit
👇 See this recap below 👇
https://www.youtube.com/watch?v=MYJ-Yyd-I8Y
